Should I buy Alkermes plc (ALKS) stock or is it too late?

Alkermes plc · Health Care · price $49
Logo Alkermes plcSee the full Alkermes plc (ALKS) profile
⭐ What the most reliable analysts say

No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.

Firm-by-firm track record on Alkermes plc

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Goldman Sachs60 %+22.4 %5$43 -12%
Mizuho60 %+20.9 %10$65 +33%
Cantor Fitzgerald83 %+10.0 %6$43 -12%
Piper Sandler83 %+6.6 %6$65 +33%
Citigroup40 %+9.7 %5
Jefferies60 %+9.5 %5
Credit Suisse60 %+4.9 %5
Barclays40 %-10.1 %5
In short — Should you invest in Alkermes plc? Is it too late, still worth it? Analysts are overwhelmingly positive (82% buy, median target $61, i.e. +25%), and the most reliable on ALKS targets even higher. But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • 82% of analysts rate it a buy (Buy consensus, 11 ratings) — a sign of market conviction.
  • Median price target $61, i.e. +25% from the current price ($49).
  • The most reliable firm on ALKS, Needham (100% hit rate, 3 scored calls), targets $62 (call made on July 13, 2026, maturing on July 13, 2027) (+27%) in its most recent call, and $44 (call made on October 29, 2025, maturing on October 29, 2026) (-10%) in the one coming due soonest.

⚠️ Reasons to hesitate

  • The consensus is not unanimous: of 11 ratings, 1 is neutral and 1 is a sell.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • No dividend: your return depends only on price appreciation.

The analyst consensus on ALKS

Median target $61 (+25%) · 11 ratings · Buy consensus

Strong Buy00%
Buy982%
Hold19%
Sell19%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Alkermes plc now?

We won't decide for you. The facts: 82% of analysts rate it a buy, median target $61 (+25%), and Needham (most reliable on ALKS, 100%) targets $62. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Alkermes plc?

Not according to analysts: the median target ($61) is still +25% above the current price ($49) (most reliable on ALKS: Needham, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Alkermes plc still worth investing in?

It depends on the gap between the price ($49) and its estimated value: analysts target $61 on median (+25%), with 82% buys (most reliable on ALKS: Needham, 100%). Cross-check with their real reliability on ALKS and the cautions above. Information, not advice.

What's the main risk in buying ALKS?

The consensus is not unanimous: of 11 ratings, 1 is neutral and 1 is a sell.

→ Go deeper: the full Alkermes plc profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)